# Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®

> **NCT00742183** · NA · COMPLETED · sponsor: **Molnlycke Health Care AB** · enrollment: 100 (actual)

## Conditions studied

- Second Degree Burn

## Interventions

- **DEVICE:** Mepilex
- **DEVICE:** Silvadene

## Key facts

- **NCT ID:** NCT00742183
- **Lead sponsor:** Molnlycke Health Care AB
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742183, "Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00742183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*